The short version of thymosin beta-4 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-14 and is reviewed periodically as new material appears.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
==== July ==== On 1 July, a National Guard member was shot dead by a Syrian government sniper, the National Guard declared it was an "explicit violation" of the ceasefire. On 2 July, the Syrian government forces clashed with the National Guard after an intense bombardment by government forces in Tel Hadid, the clashes also took place in Umm al-Zaytoun and al-Matuna, in northern Suwayda. On 7 July, the Syrian government forces bombarded the city of Al-Mazra'a with mortars, sparking clashes along the Al-Majdal and Al-Mazra'a axis. On 13 July, one year after the events of July 2025, the residents of Jaramana held a meeting to commemorate the events; at the vigil, the head of the spiritual and religious authority of Jaramana, Haitham Katiba, declared Druze dignity and their right to defend themselves. On 16 July, the events of the "Black July Week" continued, commemorating fallen Druze soldiers at the Shrine of the Martyrs in the city of Ar-Raha; in addition to the arrival of people at Al-Karama Square to participate in the popular events held to commemorate the first anniversary of the "Black July Week". On 21 July, the National Guard carried out a forced eviction at the Al-Fursan residences, targeting Alawite families, while the Syrian Observatory for Human Rights claims it was a dispute between an Alawite resident and a Druze resident. On 29 July, the Israeli far-right settler movement, Pioneers of Bashan, declared that its goal is "to create a humanitarian corridor from Israel to Suwayda", after several attempts to cross the territories occupied in the Israeli invasion.
Theranos had reportedly been on the verge of bankruptcy, with the loan meant to keep the company solvent into 2018. The loan was secured by Theranos's patents. On April 10, 2018, the company laid off the majority of workers in a renewed bid to avoid bankruptcy. The company's total headcount was now fewer than 25 employees, after having 800 employees at its peak. Softbank's Fortress bought up Theranos patents and later, taking advantage of the new market conditions in the midst of the COVID-19 pandemic, set up a shell company called Labrador Diagnostics, which sued one of the companies making COVID-19 tests, saying that its test violated those Theranos patents. Theranos was still being issued patents into 2019 because of the lengthy patent application process.
== Structure == Naringenin has the skeleton structure of a flavanone with three hydroxy groups at the 4′, 5, and 7 carbons. It may be found both in the aglycol form, naringenin, or in its glycosidic form, naringin, which has the addition of the disaccharide neohesperidose attached via a glycosidic linkage at carbon 7. Like the majority of flavanones, naringenin has a single chiral center at carbon 2, although the optical purity is variable. Racemization of (S)-(−)-naringenin has been shown to occur fairly quickly.
Sources: en.wikipedia.org
=== Data interpretation === The most common data interpretation is based on the Fresnel formulas, which treat the formed thin films as infinite, continuous dielectric layers. This interpretation may result in multiple possible refractive index and thickness values. Usually only one solution is within the reasonable data range. In multi-parametric surface plasmon resonance, two SPR curves are acquired by scanning a range of angles at two different wavelengths, which results in a unique solution for both thickness and refractive index. Metal particle plasmons are usually modeled using the Mie scattering theory. In many cases no detailed models are applied, but the sensors are calibrated for the specific application, and used with interpolation within the calibration curve.
Although Parsons had said he wanted his body cremated at Joshua Tree and his ashes spread over the formation Cap Rock, Parsons' stepfather organized a private ceremony in New Orleans and left the body in the care of a funeral home. But, to fulfill Parsons' wishes, Kaufman and a friend stole both a hearse and his body and drove it to Joshua Tree. At Cap Rock Parking Lot, they poured gasoline into the open coffin and lit it, creating an enormous fireball. They were arrested and eventually fined $750 for stealing the coffin. What remained of Parsons' body was buried in Garden of Memories Cemetery in Metairie, Louisiana. The story brings Parsons fans out to a large rock flake informally known to rock climbers as the Gram Parsons Memorial Hand Traverse. At some point, someone added a slab that marked Parsons' cremation to the memorial rock; that slab was removed by the US National Park Service and moved to the Joshua Tree Inn. Joshua Tree park guides are given the option to tell the story of Parsons' cremation during tours, but there is no mention of the act in official maps or brochures.
Chestnuts can vary widely in shade and different terms are sometimes used to describe these shades, even though they are genetically indistinguishable. Collectively, these coat colors are usually called "red" by geneticists.
Sources: en.wikipedia.org
====== Blotters ====== Blotter art designs printed on blotter paper can identify dose strengths, different batches, or makers. On the other hand, blotters without art may be considered safer by some, since there is no guarantee that the printer ink used in clandestine production is edible or non-toxic for long-term exposure, and it is also possible for unscrupulous dealers to mimic reputable blotter art designs to boost sales.
=== Antibodies === Pan-O-GlcNAc antibodies that recognize the O-GlcNAc modification largely irrespective of the modified protein's identity are commonly used. These include RL2, an IgG antibody raised against O-GlcNAcylated nuclear pore complex proteins, and CTD110.6, an IgM antibody raised against an immunogenic peptide with a single serine O-GlcNAc modification. Other O-GlcNAc-specific antibodies have been reported and demonstrated to have some dependence on the identity of the modified protein.
=== Conformational states === Simulations identified three distinct active-state conformational states of KOR: the canonical active state, an alternative state, and an occluded state. The alternative state, characterized by specific transmembrane domain conformations, correlates with β-arrestin2-biased signaling. The occluded state, in which the intracellular portion of transmembrane helix 7 rotates clockwise toward transmembrane helix 2, appears to favor G protein coupling whilst disfavoring β-arrestin recruitment. Specific residues within the receptor binding pocket differentially influence G protein versus β-arrestin signaling. Disruption of the ionic interaction by certain agonists increases the distance between the extracellular ends of transmembrane helices 5 and 6, contributing to ligand-specific transducer coupling preferences.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.